<--- Back to Details
First PageDocument Content
Trastuzumab / Breast cancer / Echocardiography / Cardiology / Radionuclide angiography / Management of cancer / Heart failure / St. Boniface General Hospital / Cardiovascular disease / Medicine / Cardiac imaging / Ribbon symbolism
Date: 2012-08-01 08:40:00
Trastuzumab
Breast cancer
Echocardiography
Cardiology
Radionuclide angiography
Management of cancer
Heart failure
St. Boniface General Hospital
Cardiovascular disease
Medicine
Cardiac imaging
Ribbon symbolism

Add to Reading List

Source URL: www.umanitoba.ca

Download Document from Source Website

File Size: 1,77 MB

Share Document on Facebook

Similar Documents

Biocon Limited: Q1 FY17 Earnings Call Transcript July 22, 2016 Participants from Biocon’s Senior Management Team Kiran Mazumdar Shaw: Chairperson and Managing Director Arun Chandravarkar: CEO & Jt. Managing Director

Biocon Limited: Q1 FY17 Earnings Call Transcript July 22, 2016 Participants from Biocon’s Senior Management Team Kiran Mazumdar Shaw: Chairperson and Managing Director Arun Chandravarkar: CEO & Jt. Managing Director

DocID: 1qxjl - View Document

Press Release  Mylan & Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency BENGALURU, India and HERTFORDSHIRE, England/PITTSBURGH, USA, July 21, 20

Press Release Mylan & Biocon Announce Regulatory Submission for Proposed Biosimilar Pegfilgrastim Accepted for Review by European Medicines Agency BENGALURU, India and HERTFORDSHIRE, England/PITTSBURGH, USA, July 21, 20

DocID: 1q6vz - View Document

Patientinformation – tillæg til DBCG 2015-b,t og 2015-d,t (Trastuzumab)  Antistofbehandling af brystkræft efter operation Denne information supplerer vores mundtlige information om den behandling, vi anbefaler dig. I

Patientinformation – tillæg til DBCG 2015-b,t og 2015-d,t (Trastuzumab) Antistofbehandling af brystkræft efter operation Denne information supplerer vores mundtlige information om den behandling, vi anbefaler dig. I

DocID: 1pKwx - View Document

FINAL  Press Release Biocon Reports a Strong Q1FY17 Revenues at Rs 952 Crore, up by 11 %; EBITDA Up 15% to Rs 271 Crore

FINAL Press Release Biocon Reports a Strong Q1FY17 Revenues at Rs 952 Crore, up by 11 %; EBITDA Up 15% to Rs 271 Crore

DocID: 1pawe - View Document

Investor Presentation June 2016 BSE: 532523 │ NSE: BIOCON │ REUTERS: BION.NS │ BLOOMBERG: BIOS IN │ WWW.BIOCON.COM

Investor Presentation June 2016 BSE: 532523 │ NSE: BIOCON │ REUTERS: BION.NS │ BLOOMBERG: BIOS IN │ WWW.BIOCON.COM

DocID: 1oSV0 - View Document